Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Challenges in treating hematologic malignancies.

Dimitris Voliotis1, Volker Diehl

  • 1Clinic I for Internal Medicine, University of Cologne, Cologne, Germany.

Seminars in Oncology
|June 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin Lymphoma.

JAMA oncology·2026
Same author

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.

Lancet (London, England)·2024
Same author

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.

Leukemia·2023
Same author

Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma.

British journal of haematology·2021
Same author

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.

The Lancet. Haematology·2021
Same author

Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).

The Lancet. Haematology·2021

Significant advancements have improved outcomes for certain hematologic malignancies, offering cures for Hodgkin

Area of Science:

  • Hematology
  • Oncology
  • Cancer Therapeutics

Background:

  • Hematologic malignancies have seen treatment progress over 40 years.
  • Cures are now attainable for Hodgkin's disease and some high-grade non-Hodgkin's lymphomas.
  • Prognoses are improving for acute leukemias, but most patients still have incurable disease.

Purpose of the Study:

  • To review the progress in treating hematologic malignancies.
  • To discuss current therapeutic paradigms and future directions.
  • To emphasize the importance of quality of life in managing these diseases.

Main Methods:

  • Review of treatment outcomes and therapeutic strategies for various hematologic malignancies.
  • Analysis of advancements in chemotherapy, radiotherapy, and targeted therapies.

Related Experiment Videos

  • Consideration of prognostic factors and their impact on treatment decisions.

    • Main Results:

    • Curative treatments exist for Hodgkin's disease and some non-Hodgkin's lymphomas.
    • Molecular remissions are achievable in indolent lymphomas using new drugs and monoclonal antibodies.
    • Challenges remain in preventing early relapse and treating primary resistant disease in Hodgkin's lymphoma.

    Conclusions:

    • While cures are possible for some hematologic cancers, many remain incurable.
    • New therapies offer hope for molecular remissions, but long-term survival benefits require further study.
    • Preserving quality of life is a critical aspect of managing all hematologic malignancies.